Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-phenylthiobutanoic acid
- Development stage
- Preclinical
- Lead developer
- University of Pittsburgh
- Modality
- Small Molecules
01
Overview
4-phenylthiobutanoic acid (PTBA) is a small molecule histone deacetylase (HDAC) inhibitor that selectively targets histone deacetylase 8 (HDAC8). Discovered through a pathway-agnostic, cell proliferation-based phenotypic screen in zebrafish, PTBA has been shown to promote the proliferation of renal tubular epithelial cells (RTECs) and cardiac progenitor cells. This activity enhances tissue repair and reduces post-injury fibrosis in animal models of acute kidney injury (AKI) and cardiac injury. To overcome the permeability limitations of the parent carboxylic acid, esterified prodrugs such as UPHD25 and UPHD186 have been developed to deliver PTBA in vivo.
- Other names
- 4-(phenylthio)butanoic acid4-phenylthiobutyric acidPTBA
02
Targets
HDAC8 (Histone Deacetylase 8)
Beyond the preview
Go deeper on 4-phenylthiobutanoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-phenylthiobutanoic acid.